If health disparities are taken into account, a cure for sickle cell will be affordable, a study reveals.

If health inequities linked in part to lower access to healthcare are taken into consideration, experts said at a gathering of blood-disease specialists, multimillion-dollar gene treatments being studied for sickle cell disease will be cost-effective in the United States. According to the US Cent...